KK2260
/ Kyowa Kirin
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 05, 2025
A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=169 | Recruiting | Sponsor: Kyowa Kirin Co., Ltd. | Trial completion date: May 2029 ➔ Apr 2030 | Trial primary completion date: Nov 2028 ➔ Oct 2029
Trial completion date • Trial primary completion date • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CRP
March 06, 2024
KK2260: A fully human tetravalent bispecific antibody targeting TfR1 and EGFR for the treatment of EGFR-expressing tumors
(AACR 2024)
- "KK2260 demonstrated potent anti-cancer effect both in vitro and in vivo. Intriguingly, KK2260 did not inhibit EGFR phosphorylation while EGFR-binding dependent TfR1 downregulation resulted in intracellular iron deficiency, which was considered as the MOA of KK2260. KK2260 was well tolerated in non-human primates."
Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma • EGFR • TFRC
February 08, 2024
A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=139 | Recruiting | Sponsor: Kyowa Kirin Co., Ltd.
New P1 trial • Esophageal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CRP
1 to 3
Of
3
Go to page
1